Jan 23, 2026Health systems nationwide have raised concerns regarding current vulnerabilities in the exchange of electronic health records. This article explores the motivations behind their collective appeal, the risks posed by inadequate data security, and the broader implications for patient care and regulatory reform.
The Catalyst Brief
Jan 23, 2026The rare pediatric disease priority review voucher program, a key FDA initiative designed to incentivize drug development for rare pediatric diseases, faced uncertainty after missing reauthorization in 2024. The recent House spending bill vote signals potential for revival as the bill moves to the Senate.
The Catalyst Brief
Jan 23, 2026Amid rising healthcare expenses and growing scrutiny, lawmakers conducted two House hearings to interrogate health insurance CEOs. The discussions revealed key insights into the industry's stance on cost drivers, structural market dynamics, and administrative hurdles that affect patient care and system efficiency.
The Catalyst Brief
Jan 21, 2026The removal of Ash, a therapy chatbot developed by Slingshot AI, from the UK market highlights the increasing scrutiny and regulatory challenges faced by digital therapeutic tools. This article analyzes the regulatory environment, the implications for digital mental health products, and the broader context of AI-driven therapies.
The Catalyst Brief
Jan 20, 2026After previously being stymied, elements of a bipartisan health care package have reemerged in Congressional discussions. Central to the proposal are updated regulations on pharmacy benefit managers and strategies to mitigate drug pricing inflation, reflecting the complexity and urgency in reforming the U.S. health care system.
The Catalyst Brief
Jan 19, 2026The 2026 J.P. Morgan Healthcare Conference illuminated critical themes in biotech regulatory affairs. Companies conveyed a collective push for harmony with the FDA concerning clinical trial protocols and expedited approval pathways. Nonetheless, the conference also underscored ongoing regulatory complexities through cases like Atara’s recent therapy denial.
The Catalyst Brief
Jan 17, 2026The updated food pyramid, a cornerstone of public health nutrition advice, has emerged amid criticism regarding opaque scientific practices and the influence of industry funding on the scientific panel responsible for its creation. This post unpacks the challenges and pressures faced during the guideline development process.
The Catalyst Brief
Jan 17, 2026Rotavirus, a leading cause of severe diarrhea in young children, was once broadly prevented through universal vaccination programs. However, recent changes in vaccine recommendations have sparked debate among experts concerning public health outcomes and preventable disease burdens.
The Catalyst Brief
Jan 16, 2026Recent data from South Carolina's state health officials reveal a nearly 30% increase in reported measles cases over the last few days, reaching more than 550 cases. This resurgence poses critical questions about vaccination coverage, outbreak containment, and healthcare system preparedness.
The Catalyst Brief
Jan 16, 2026The settlement marks one of the largest risk-adjustment settlements in recent history, underscoring ongoing federal scrutiny of Medicare Advantage programs. This case highlights the complexities and regulatory challenges facing healthcare organizations operating within government programs.
The Catalyst Brief
Jan 15, 2026Jazz Pharmaceuticals recently sold one of its Priority Review Vouchers (PRVs) for $200 million, marking a substantial financial transaction as the future of the PRV program hangs in the balance due to legislative delays. The details of the buyer remain undisclosed, and the allocation of the remaining proceeds is unclear, emphasizing the nuanced complexities in biotech regulatory incentives.
The Catalyst Brief
Jan 15, 2026The burgeoning weight loss drug market has recently faced legal scrutiny as a compounding pharmacy alleges anticompetitive tactics by leading biopharmaceutical companies Eli Lilly and Novo Nordisk. This lawsuit brings further attention to the competitive dynamics and regulatory challenges in the obesity treatment sector.
The Catalyst Brief